Loading…
Employees: 24
Size Benitec Biopharma (BNTC) is a United States Health Care company (Biotechnology) with a market value of $333M, the 3022nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $9.54 on 6 Nov 2026.
Performance Over six months the shares fell 22.3%, against -26.6% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 18 in its peer set.
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $75,000 |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -$481,000 | -$481,000 | -$396,000 | -$343,000 | -$306,000 |
| EBITDA | -$50.7M | -$50.7M | -$41.4M | -$22.3M | -$18.7M |
| Net income | -$45.5M | -$45.5M | -$37.9M | -$21.8M | -$19.6M |
| Free cash flow | -$17.4M | -$16.6M | -$23.6M | -$19.6M | -$18.0M |
| Capital expenditure | $109,932 | $105,000 | $18,000 | $179,000 | $1,000 |
| Total debt | $762,000 | $762,000 | $849,000 | $284,000 | $559,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BNTC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.0% | -13.5% | 5th highest of 20 |
| 6-month return | -22.3% | -26.6% | 8th highest of 18 |
| Distance from 52-week high | -33.7% | -53.8% | 4th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | 4.8× | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | 9.9× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | 36.4× | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | 4.4× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | 11.6× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Medy-Tox 086900.KS | South Korea | $310M | -39% | +7% | 7% | 2.0× | 6.0% | +11.9% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |